Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
,
Gastrointestinal side effects remain among the most common challenges during GLP-1 therapy, with diarrhea reported in clinical studies at rates between 20-25% depending on dose and medication type
Both Novo Nordisk and Eli Lilly, alongside other Big Pharma players, have pursued or are pursuing additional trials and research exploring additional diseases and conditions where GLP-1 drugs and their successors may be effective treatments
Factors like medical history, cost, insurance coverage, and potential side effects all play a role
Dual Mechanism of Actio n: By targeting both the GLP-1 and GIP receptors simultaneously, Mounjaro aims to achieve better results in managing blood sugar levels and promoting weight loss compared to medications that only focus on one pathway
Mochi also does not require labs for all patients
US$ 24.84
US$ 29.36
US$ 22.32
US$ 29.11
US$ 29.38
US$ 22.22
